Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 471Neoplasms 328Colorectal Neoplasms 235Carcinoma, Non-Small-Cell Lung 234Lung Neoplasms 200Prostatic Neoplasms 179Carcinoma, Hepatocellular 174Stomach Neoplasms 138Pancreatic Neoplasms 126Leukemia, Myeloid, Acute 114Uterine Cervical Neoplasms 110Rectal Neoplasms 105Multiple Myeloma 94Recurrence 89Squamous Cell Carcinoma of Head and Neck 84Head and Neck Neoplasms 79Neoplasm Metastasis 76Ovarian Neoplasms 75Brain Neoplasms 71Colonic Neoplasms 68Glioblastoma 67Esophageal Neoplasms 66Triple Negative Breast Neoplasms 65Endometrial Neoplasms 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Small Cell Lung Carcinoma 54Disease 54Motor Activity 53Hematologic Neoplasms 53Glioma 48

Interventions

Radiofrequency Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × Multiple Advanced Tumors After PD-1 Therapy Failure × Clear all
NCT07095803 2025-07-31

Ivonescimab (PD-1/VEGF Bispecific Antibody) Plus Radiofrequency Ablation for Multiple Advanced Tumors After PD-1 Therapy Failure

Fudan University

Phase 2 Not yet recruiting
60 enrolled

Multiple Advanced Tumors After PD-1 Therapy Failure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡